256 related articles for article (PubMed ID: 33854160)
21. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
22. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
23. Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma.
Diaz G; Engle RE; Tice A; Melis M; Montenegro S; Rodriguez-Canales J; Hanson J; Emmert-Buck MR; Bock KW; Moore IN; Zamboni F; Govindarajan S; Kleiner DE; Farci P
Mol Cancer Res; 2018 Sep; 16(9):1406-1419. PubMed ID: 29858376
[TBL] [Abstract][Full Text] [Related]
24. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
25. Innate immune recognition and modulation in hepatitis D virus infection.
Jung S; Altstetter SM; Protzer U
World J Gastroenterol; 2020 Jun; 26(21):2781-2791. PubMed ID: 32550754
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.
Ferrante ND; Lo Re V
Curr HIV/AIDS Rep; 2020 Aug; 17(4):405-414. PubMed ID: 32607773
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.
Manesis EK; Vourli G; Dalekos G; Vasiliadis T; Manolaki N; Hounta A; Koutsounas S; Vafiadis I; Nikolopoulou G; Giannoulis G; Germanidis G; Papatheodoridis G; Touloumi G
J Hepatol; 2013 Nov; 59(5):949-56. PubMed ID: 23850875
[TBL] [Abstract][Full Text] [Related]
28. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
29. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis D Virus and Hepatocellular Carcinoma.
Farci P; Niro GA; Zamboni F; Diaz G
Viruses; 2021 May; 13(5):. PubMed ID: 34064419
[TBL] [Abstract][Full Text] [Related]
31. Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation.
Baskiran A; Akbulut S; Sahin TT; Koc C; Karakas S; Ince V; Yurdaydin C; Yilmaz S
Hepatol Int; 2020 Sep; 14(5):869-880. PubMed ID: 32895876
[TBL] [Abstract][Full Text] [Related]
32. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
33. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta.
Roulot D; Brichler S; Layese R; BenAbdesselam Z; Zoulim F; Thibault V; Scholtes C; Roche B; Castelnau C; Poynard T; Chazouillères O; Ganne N; Fontaine H; Gournay J; Guyader D; Le Gal F; Nahon P; Roudot-Thoraval F; Gordien E;
J Hepatol; 2020 Nov; 73(5):1046-1062. PubMed ID: 32634548
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study.
Buti M; Homs M; Rodriguez-Frias F; Funalleras G; Jardí R; Sauleda S; Tabernero D; Schaper M; Esteban R
J Viral Hepat; 2011 Jun; 18(6):434-42. PubMed ID: 20546496
[TBL] [Abstract][Full Text] [Related]
35. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies.
Kamal H; Fornes R; Simin J; Stål P; Duberg AS; Brusselaers N; Aleman S
J Viral Hepat; 2021 Oct; 28(10):1431-1442. PubMed ID: 34291520
[TBL] [Abstract][Full Text] [Related]
36. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
[TBL] [Abstract][Full Text] [Related]
37. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients.
Kim DS; Park SY; Kim BK; Park JY; Kim DY; Han KH; Lee YR; Tak WY; Kweon YO; Jung I; Han M; Kim EH; Ahn SH; Kim SU
J Korean Med Sci; 2021 Apr; 36(16):e105. PubMed ID: 33904261
[TBL] [Abstract][Full Text] [Related]
38. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
Romeo R; Del Ninno E; Rumi M; Russo A; Sangiovanni A; de Franchis R; Ronchi G; Colombo M
Gastroenterology; 2009 May; 136(5):1629-38. PubMed ID: 19208358
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.
Spaan M; Carey I; Bruce M; Shang D; Horner M; Dusheiko G; Agarwal K
J Hepatol; 2020 Jun; 72(6):1097-1104. PubMed ID: 31981726
[TBL] [Abstract][Full Text] [Related]
40. High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses.
Oyunsuren T; Kurbanov F; Tanaka Y; Elkady A; Sanduijav R; Khajidsuren O; Dagvadorj B; Mizokami M
J Med Virol; 2006 Dec; 78(12):1688-95. PubMed ID: 17063518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
